Seed capital allocation, per-compound unit economics, break-even analysis, three growth scenarios, and tax-optimised structure β a capital-efficient path to profitability
A peptide e-commerce launch requires disciplined capital allocation. The β¬40,000 seed budget is structured to maximise operational readiness while preserving a meaningful buffer for the unexpected.
First-purchase quantities across six compounds β BPC-157, TB-500, Semaglutide, Tirzepatide, AOD-9604, GHK-Cu β sourced through pre-vetted manufacturers with documented purity certificates and independent COAs. Product mix: ~30% BPC-157 (highest volume), ~20% Semaglutide/Tirzepatide (higher unit cost), ~50% across remaining four SKUs.
Every batch carries a Janoshik Analytical COA β full-panel HPLC purity testing and mass spectrometry confirmation for all six compounds. Amortised across ~500 units (~β¬6/vial). Treated as a fixed cost; batch retesting built into monthly fixed costs after initial β¬3,000 is exhausted.
Padded poly mailers, silica gel desiccant packs, temperature-stable insulated packaging, discreet outer packaging, plus initial postage float for 60β80 shipments. Tracked EU shipping via national postal operators β keeps per-order logistics under β¬10 within the eurozone.
2 mL and 5 mL amber glass vials with rubber stoppers and crimp seals, tamper-evident labels, printed insert leaflets in multiple EU languages, QR code integration linking to downloadable COAs. Presentation drives repeat orders.
Shopify or WooCommerce build with medical-aesthetic design, priority SSL, EU-compliant cookie consent (Cookiebot/Osano), 8β12 high-resolution product images, payment gateway integration.
Stripe or Mollie account configuration, merchant verification for supplement-adjacent category, multicurrency setup, initial transaction fee minimums.
s.p. sole proprietorship establishment with Slovenian business registry, tax advisor consultation, GDPR-compliant privacy policy, product-specific research-use-only disclaimers, OSS VAT registration filing for cross-border EU sales.
Untouched through first two months. Covers: delayed inventory β emergency restock, chargeback wave β frozen merchant reserve, customs hold β bond payment, product pivot β new sourcing, regulatory inquiry β legal consultation. Drawn down only with explicit justification, tracked separately, replenished as priority once cash-flow positive.
Each of the six target compounds has a distinct cost profile driven by synthesis complexity, purification difficulty, supply dynamics, and competitive retail pricing.
| Compound | Vial Size | Cost/Unit | Retail Price | Margin % | Abs. Contribution | Strategy |
|---|---|---|---|---|---|---|
| BPC-157 | 5 mg | β¬11β16 | β¬30β45 | 60β65% | ~β¬19 | Volume driver, competitive pricing (β¬32β35) |
| TB-500 | 5 mg | β¬14β19 | β¬35β50 | 58β62% | ~β¬24 | Bundle upsell with BPC-157 (10β15% discount) |
| Semaglutide | 5 mg | β¬35β45 | β¬60β80 | 40β48% | ~β¬30 | Acquisition funnel; higher CLV customer segment |
| Tirzepatide | 5 mg | β¬40β55 | β¬80β120 | 45β50% | ~β¬40 | Highest absolute β¬/sale; stock in smaller batches |
| AOD-9604 | 5 mg | β¬10β15 | β¬30β45 | 62β67% | ~β¬22 | Highest % margin; mature commoditised supply chain |
| GHK-Cu | 50 mg | β¬7β12 | β¬20β30 | 55β63% | ~β¬16 | Entry-level product; strong perceived value |
BPC-157 + TB-500 bundle at 10β15% off combined standalone price lifts average order value from ~β¬45 (single vial) to ~β¬70 β improving contribution margin by roughly β¬15 per order.
Semaglutide and Tirzepatide accept lower percentage margins (40β50%) because they draw a higher-CLV customer segment and produce strong absolute euro contributions per sale (β¬30β40 vs ~β¬20 for core compounds).
The financial model targets cash-flow break-even within 3β6 months via a deliberately achievable monthly order target of 37 orders.
β¬50/mo β Shopify Basic (β¬32) or WooCommerce VPS hosting (β¬40), plus annual domain amortisation (~β¬10/mo)
β¬30/mo β Stripe/Mollie monthly account fee and minimum terminal fee (before per-transaction charges)
β¬250/mo β Non-negotiable for EU peptide space even with research-use-only disclaimers. Available from Slovenian/EU insurers.
β¬200/mo β Mailers, desiccant packs, cold-chain insulation (6 warm months), replacement labels and inserts
β¬250/mo β One full Janoshik HPLC + mass-spec panel covering ~40 vials across the catalogue each month
β¬300/mo β Targeted Reddit peptide community ads, forum sidebar placements, SEO content (1 Γ 800-word article/week)
β¬200/mo β Printer toner, inventory tracking software, support ticket system, bank fees, courier surcharges
| Line Item | Amount | Notes |
|---|---|---|
| Cost of Goods Sold | β¬24 | Weighted avg. β¬12/vial Γ 2 vials per order |
| Packaging & Shipping | β¬12 | Tracked EU delivery + branded materials |
| Payment Processing (5%) | β¬4 | Blended card-not-present rate for peptide category |
| Testing Amortisation | β¬5 | ~β¬2.50/vial COA cost Γ 2 vials |
| Total Variable Costs | β¬45 | ββ |
| Contribution Margin | β¬35 | β¬80 AOV β β¬45 variable costs |
Inventory Turn Velocity is the Primary Financial Risk. If stock does not move at the projected rate, capital is physically trapped on the shelf. Weekly stock-turn analysis compares actual turns against targets per SKU, and slow-moving Semaglutide/Tirzepatide stock is promoted through bundle discounts to convert trapped capital back into operating cash.
The model stress-tests core assumptions across three scenarios with concrete operational milestones and trigger points for decision-making.
| Metric | π’ Conservative | π― Target | π Growth |
|---|---|---|---|
| Orders / Month | 20 | 60 | 150 |
| Monthly Revenue | β¬1,600 | β¬4,800 | β¬12,000 |
| Gross Profit | β¬960 | β¬3,360 | β¬8,400 |
| Blended Margin | 60% | 70% | 70% |
| Net Profit (after β¬1,280 fixed costs) | ββ¬320 | +β¬2,080 | +β¬7,120 |
| Net Margin | β20% | ~43% | ~59% |
| Inventory Recovery | 15.6 months | 5.2 months | 2.1 months |
| Phase | Months 1β2 | Months 3β6 | Months 6β12 |
Zero social proof, first COAs uploading, brand awareness at zero. Loss of ββ¬320/mo survivable for 2β3 months from the β¬7,000 reserve. No additional marketing spend beyond baseline β¬300/mo. If still in conservative territory at month 3, pull the reserve-funded marketing lever.
12+ verified reviews, first SEO rankings bringing organic traffic ("buy research peptides EU", "BPC-157 Slovakia"), 20β30% repeat customers. Margin improves from 60% β 70% via volume discounts, negotiated shipping rates, and larger batch testing. At 60 orders, the business is profitable, sustainable, and generating cash for reinvestment.
+β¬7,120/mo net profit. Strategic decisions: reinvest into additional compounds (Tesofensine, MOTS-C, SS-31), d.o.o. transition, founder salary, part-time assistant. New challenges: chatbot automation needed for 150 orders/mo, inventory management shifts to ERP-lite (Cin7/TradeGecko).
Below target at month 3 β reserve-funded influencer collab or larger ad test. Above target before month 6 β accelerate d.o.o. transition and product line expansion. Still below 20 orders at month 4 β critically re-evaluate product mix; dropping Semaglutide/Tirzepatide may improve conversion rate on remaining 4 products.
~4% effective tax rate on revenue. 80% of gross revenue automatically deemed expenses β only 20% is taxable. At 20% personal income tax bracket, β¬60K revenue β β¬2,400 tax due. No corporate profit tax, no dividend withholding, no quarterly estimates. Annual return is straightforward with no full-time accountant required.
Capped at ~β¬100K revenue threshold β benefit phases out above that. Personal assets fully exposed to business debts, legal claims, or regulatory penalties. In the peptide space where regulatory frameworks vary across EU member states, this liability exposure is the single most significant risk in the operating model.
Transition triggered at year 2, or earlier if monthly revenue exceeds ~β¬6,000 for 3 consecutive months. Provides full liability separation. Retained earnings taxed at 22% corporate rate. Distributed profits face combined ~42% effective rate (22% corporate + ~25% dividend withholding). Strategy: maximise retained earnings for reinvestment.
Reinvesting profits into inventory, warehousing equipment, marketing, or technology keeps tax at 22% (corporate rate only). No dividend tax triggered until personal withdrawal. For a scaling peptide company, retaining profits for 2β3 years before significant distributions is both standard practice and highly tax-efficient.
| Structure | Tax Base | Effective Rate | Liability Protection | Revenue Cap | Recommended |
|---|---|---|---|---|---|
| s.p. Normirani StroΕ‘ki | 20% of revenue | ~4% | β No | ~β¬100K | Year 1 |
| d.o.o. (retained) | Net profit | ~22% | β Yes | Unlimited | Year 2+ if growing |
| d.o.o. (distributed) | Distributed profit | ~42% | β Yes | Unlimited | Only after growth phase |
The EU One-Stop Shop regime, introduced 1 July 2021, eliminates the need for separate VAT registration in every member state. A single quarterly OSS filing in Slovenia covers all cross-border B2C sales across all 27 EU countries.
Register for VAT in Slovenia. File a single quarterly OSS return covering all distance B2C sales within the EU. Applicable VAT rate = customer's country rate, not seller's. Single payment to the Slovenian tax authority, which handles inter-governmental redistribution. Filed via eDavki portal.
Germany: 19% Β· France: 20% Β· Italy: 22% Β· Slovenia (domestic): 22% Β· Spain: 21% Β· Netherlands: 21%
List prices displayed including VAT is cleaner; VAT is a pass-through liability with no effect on gross profit or contribution margin.
There is no small-seller de minimis exemption for distance sales under current rules. From the very first cross-border transaction, OSS applies. Setup automatic VAT calculation at launch β retroactively fixing mis-collected VAT is far more expensive.
Shopify and WooCommerce both support EU VAT plugins (Avalara, TaxJar, native Shopify EU VAT). These validate customer country at checkout, apply correct rate, record EDD data, and generate quarterly OSS reports as downloadable CSVs. Critical: configure before launch, not after.
The following table consolidates critical numbers for quick reference and ongoing tracking β reviewed weekly in months 1β3, monthly thereafter.
| Category | Metric | Value |
|---|---|---|
| π° Capital | Total Seed Capital | β¬40,000 |
| Largest Deployment | Inventory β β¬22,500 (56%) | |
| Reserve Buffer | β¬7,000 (17.5%) β ~4 months runway at zero revenue | |
| π Unit Economics | Avg. Order Value | β¬80 |
| Variable Costs / Order | β¬45 (COGS β¬24 + shipping β¬12 + processing β¬4 + testing β¬5) | |
| Contribution Margin | β¬35/order | |
| π Break-Even | Monthly Orders to B/E | 37 orders/mo = β¬2,960 revenue |
| Inventory Recovery | 312 orders (5.2 months at target volume) | |
| π― Target Scenario | Volume | 60 orders/mo β β¬4,800 revenue β +β¬2,080 net profit |
| Phase | Months 3β6 | |
| π Growth Scenario | Volume | 150 orders/mo β β¬12,000 revenue β +β¬7,120 net profit |
| Phase | Months 6β12 | |
| ποΈ Tax | Year 1 (s.p.) | ~4% effective tax on revenue (normirani stroΕ‘ki) |
| Year 2+ (d.o.o.) | ~22% on retained profit; ~42% on distributed profit | |
| π VAT | Cross-border EU | Single quarterly OSS filing from Slovenia β no separate MS registrations |
The financial model describes a lean, capital-efficient launch with a clear path to profitability within 4β6 months of the first customer order. The blended gross margin across the six-compound catalogue runs approximately 65%, the fixed cost base is minimised through a solo-operation structure at β¬1,280/mo, and the tax regime is optimised for early-stage growth and capital preservation. The β¬7,000 reserve provides a meaningful safety margin against unforeseen contingencies that inevitably arise in any e-commerce launch.